Rethinking First-Line Anticoagulation in Older Adults: Real-World Evidence Challenges Conventional AFib Management

Rethinking First-Line Anticoagulation in Older Adults: Real-World Evidence Challenges Conventional AFib Management

A large-scale study of 144,969 Medicare beneficiaries reveals that initial anticoagulant prescriptions for atrial fibrillation may not reduce ischemic stroke risk in patients over 66, while significantly increasing major bleeding hazards, suggesting a need for more nuanced, individualized clinical decision-making.
Emergent Carotid Stenting During Thrombectomy Superior for Tandem Lesion Stroke: Insights From the CERES-TANDEM Study

Emergent Carotid Stenting During Thrombectomy Superior for Tandem Lesion Stroke: Insights From the CERES-TANDEM Study

The CERES-TANDEM study provides Class II evidence that emergent carotid stenting (eCAS) during endovascular thrombectomy for tandem lesions significantly improves 90-day functional outcomes without increasing hemorrhagic risk, supporting its integration into clinical practice for acute anterior circulation ischemic stroke.
Refining Risk Stratification: The IsCHEMiA Score Outperforms Existing Models in Predicting Poststroke Epilepsy

Refining Risk Stratification: The IsCHEMiA Score Outperforms Existing Models in Predicting Poststroke Epilepsy

The IsCHEMiA score, an imaging-based risk model validated across international cohorts, offers superior prediction of poststroke epilepsy compared to previous tools. By integrating clinical and neuroimaging markers, it provides a precise framework for personalized management and the design of future antiepileptogenic clinical trials.
No Net Benefit from Adding Antiplatelet Therapy to Anticoagulation After Ischemic Stroke With Atrial Fibrillation and Atherosclerosis — Higher Bleeding Risk

No Net Benefit from Adding Antiplatelet Therapy to Anticoagulation After Ischemic Stroke With Atrial Fibrillation and Atherosclerosis — Higher Bleeding Risk

In a randomized trial of 316 patients with ischemic stroke/TIA, nonvalvular atrial fibrillation, and atherosclerotic disease, adding an antiplatelet to anticoagulation did not reduce ischemic events but doubled clinically relevant bleeding compared with anticoagulant monotherapy.
General Anesthesia May Improve 90‑Day Outcomes and Reperfusion After EVT for Large‑Vessel Ischemic Stroke: Key Takeaways from the SEGA Randomized Trial

General Anesthesia May Improve 90‑Day Outcomes and Reperfusion After EVT for Large‑Vessel Ischemic Stroke: Key Takeaways from the SEGA Randomized Trial

The SEGA randomized trial suggests general anesthesia (GA) during endovascular therapy for large‑vessel occlusion stroke may lead to better 90‑day functional outcomes and higher reperfusion rates than moderate sedation, though credible intervals overlap and uncertainties remain.
Evaluating Electromagnetic Network-Targeted Field Therapy for Post-Ischemic Stroke Disability: Insights from the EMAGINE Trial

Evaluating Electromagnetic Network-Targeted Field Therapy for Post-Ischemic Stroke Disability: Insights from the EMAGINE Trial

The EMAGINE randomized clinical trial assessed low-intensity electromagnetic stimulation combined with rehabilitation in moderate to severe ischemic stroke patients. While safe, it did not yield statistically significant functional improvement, warranting further investigation.